Breaking News Indicates PSTI's Cell Therapy for Bone Marrow Could Be A Blockbuster |
![]() |
![]() |
By Ray Dirks of Ray Dirks Research | |
Monday, 06 August 2012 01:46 | |
It might be easy to believe this was a fluke, but the company has just done it again. This time, the patient was a middle-aged woman with lymphoma who had radiation and chemotherapy and, like the girl, did not respond to bone marrow transplants, becoming sicker, with no chances left. Also like the girl, she received only two intramuscular injections of PLX cells one week apart. Two weeks later, her blood cell count was back to normal and she was released in good health.
Israeli TV networks are all over this ground-breaking story and it is certainly big news for a reason.
Cancer companies command huge take-out premiums. Speculation over Medivation, Inc. (NASDAQ:MDVN) with its experimental cancer drug made shares rise 300% this year. Pluristem, using a platform technology that has been successful in diseases of the leg arteries, heart, and lungs, all multi-billion dollar markets, has found what looks like an answer for patients with no options but death. We note also that The Maxium Group initiated coverage with a buy on Pluristem just a few days ago. That firm also note a price target of $8.00 a share. Think about that. About Ray Dirks Ray Dirks came to Wall Street with Goldman, Sachs & Co. in 1963 where he was established as the leading insurance stock analyst dealing with institutional investors and high-net worth investors both in the U.S. and internationally. Ray’s research includes Healthcare Stocks and Special Situations. Ray has written two books, “The Great Wall Street Scandal” and “Heads You Win, Tails You Win,” published by McGraw-Hill and Bantam Books respectively. He continues to provide research to institutions and individuals. ![]() "Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'. Add this page to your favorite Social Bookmarking websites ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |